SCHEMBL14045752

SCHEMBL14045752

CCN(CCCN1CCOCC1)C(=O)N[C@@H](C)c1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.56
F10 P00742 1/20 0.46
F7 P08709 1/20 0.46
CCR4 P51679 2/20 0.45
ALDH1A1 P00352 2/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
EPHX2 P34913 2/20 0.43
TSHR P16473 1/20 0.43
CASR P41180 1/20 0.43
RECQL P46063 1/20 0.42
SSTR4 P31391 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14045749 0.88 NPSR1 (0.55) NPSR1CCR4ALDH1A1USP2PKM
SCHEMBL14025762 0.88 NPSR1 (0.50) NPSR1F10F7CCR4ALDH1A1
SCHEMBL14025021 0.88 NPSR1 (0.50) NPSR1F10F7CCR4ALDH1A1
SCHEMBL14067958 0.87 NPSR1 (0.53) NPSR1F10F7CCR4ALDH1A1
SCHEMBL4924392 0.87 NPSR1 (0.53) NPSR1F10F7CCR4ALDH1A1
SCHEMBL4924403 0.87 NPSR1 (0.53) NPSR1F10F7CCR4ALDH1A1
SCHEMBL14068258 0.87 NPSR1 (0.52) NPSR1CCR4ALDH1A1USP2PKM
SCHEMBL14025153 0.87 NPSR1 (0.52) NPSR1CCR4ALDH1A1USP2PKM
SCHEMBL4787670 0.87 NPSR1 (0.51) NPSR1F10F7CCR4ALDH1A1
SCHEMBL4787665 0.87 NPSR1 (0.51) NPSR1F10F7CCR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A NPSR1 4497/4885F10 3356/4885F7 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.